[PRE-ECLAMPSIA: A NEW TEST FOR AN OLD DISEASE].

In the western world, pre-eclampsia, diagnosed in 3-5% of pregnant women, is a major cause of maternal and fetal morbidity and mortality. Once pre-eclampsia is diagnosed, the only effective treatment is delivery. There are known historical risk factors for the development of pre-eclampsia, however only 30% of the women who will develop pre-eclampsia are identified based on their presence.

Termination of pregnancy due to renal tract abnormalities: survey of 97 fetuses from a single medical center.

Objective: The article aimed to assess the spectrum of fetal renal tract abnormalities as a major finding leading to termination of pregnancy (TOP).

Method: The study population included all pregnant women with singleton pregnancy who underwent TOP in our institute because of fetal renal tract indications between 1998 and 2015. We specifically excluded TOPs performed because of multiple pregnancies, multisystem defects, abnormal karyotype and chromosomal or genetic defect not related to renal tract abnormalities.

Does estrogen directly modulate anti-müllerian hormone secretion in women?

Objective: To investigate whether estrogen may modulate anti-müllerian hormone (AMH) expression in women.

Design: Prospective analysis.

Setting: Fertility clinic of tertiary university hospital.

The risk of malignancy in post-menopausal women presenting with adnexal torsion.

Objectives: Adnexal torsion is usually diagnosed in pre-menopausal women and is less common in post-menopausal patients. The risk of malignancy in cases of torsion in menopausal patients is not known. We set out to describe our experience with adnexal torsion in post-menopausal women and to discuss issues related to management in this situation.

The effect of the homeopathic remedies Arnica montana and Bellis perennis on mild postpartum bleeding--a randomized, double-blind, placebo-controlled study--preliminary results.

Objective: To evaluate the effect of Arnica Montana and Bellis perennis on postpartum blood loss.

Design: Double blind, placebo-controlled, randomized, clinical trial.

Setting: Department of Gynecology, Shaare Zedek Medical Center, Jerusalem.